Drug Interaction Report

Nirmatrelvir and Cariprazine: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Cariprazine

Vraylar Vraylar®
+

Nirmatrelvir

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 16, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 72 documented Nirmatrelvir interactions, 55 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Effects may be stronger Theoretical
The Bottom Line
Paxlovid can raise cariprazine levels and side effects, so your care team will likely lower your cariprazine dose during the short course and raise it again afterward. Don't change doses yourself; check with your pharmacist or doctor.

Here's what's going on. Paxlovid contains two medicines, one of which (ritonavir) is a strong blocker of a liver enzyme (CYP3A4) that helps break down your cariprazine (Vraylar). When that enzyme is slowed down, more cariprazine can build up in your body, which can mean stronger side effects like restlessness, sleepiness, muscle stiffness, or unusual movements.

The good news is this is very manageable. Your care team can lower your cariprazine dose while you're on the short Paxlovid course and then bring it back up afterward. Please don't change anything on your own. Just let your pharmacist or doctor know you take both so they can plan the right dose for you.

Mechanism/direction: Ritonavir (a component of nirmatrelvir/ritonavir) is a strong CYP3A4 inhibitor; cariprazine is a CYP3A4 substrate. Inhibition reduces clearance and increases cariprazine (and active metabolite) exposure, raising risk of dose-related adverse effects (EPS, akathisia, somnolence).

  • Severity: Major. Evidence: theoretical. Onset: unspecified.
  • Management (per labeling): If adding ritonavir to established cariprazine, reduce current dose by ~50% (4.5 mg/day to 1.5-3 mg/day; 1.5 mg/day to every other day).
  • Initiating cariprazine on ritonavir: 1.5 mg on days 1 and 3 (none day 2), then 1.5 mg/day from day 4, max 3 mg/day.
  • On ritonavir withdrawal, increase cariprazine dose back toward baseline. Monitor for EPS/sedation.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

Increased cariprazine exposure

Interaction Deep Dive

Taking nirmatrelvir/ritonavir together with cariprazine can raise cariprazine exposure, so the cariprazine dose should be modified when required2. In patients who are already on cariprazine and are being started on ritonavir (a strong CYP3A4 inhibitor), cut the existing cariprazine dose in half. Those receiving cariprazine 4.5 mg/day should be lowered to either 1.5 mg or 3 mg daily, whereas patients on 1.5 mg/day should switch to every-other-day dosing. For a patient already established on ritonavir in whom cariprazine is being initiated, give cariprazine 1.5 mg on days 1 and 3, with no dose on day 2. Beginning on day 4, provide 1.5 mg/day, titrating upward as required up to a ceiling of 3 mg/day. If ritonavir is later discontinued, the cariprazine dose should be raised 1.

Why it happens (mechanism)

Unknown

How to manage this interaction

Keep taking both as prescribed unless your care team tells you otherwise. Because Paxlovid is a short course, your team can adjust cariprazine around it.

  • Tell your pharmacist and prescriber you take cariprazine before starting Paxlovid.
  • Your cariprazine dose may be lowered (often reduced by about half) while you're on Paxlovid, then increased back afterward. Your team will individualize this.
  • Watch for signs of too much cariprazine: increased restlessness, muscle stiffness, tremor, or drowsiness, and report them.

This is a well-understood situation your care team can plan for.

Management is individual — confirm any change with your pharmacist or prescriber.

Common questions

Can I take Nirmatrelvir and Cariprazine together?

Paxlovid can raise cariprazine levels and side effects, so your care team will likely lower your cariprazine dose during the short course and raise it again afterward. Don't change doses yourself; check with your pharmacist or doctor. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Nirmatrelvir and Cariprazine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Nirmatrelvir and Cariprazine interaction managed?

Keep taking both as prescribed unless your care team tells you otherwise. Because Paxlovid is a short course, your team can adjust cariprazine around it. Tell your pharmacist and prescriber you take cariprazine before starting Paxlovid. Your cariprazine dose may be lowered (often reduced by about half) while you're on Paxlovid, then increased back afterward. Your team will individualize this. Watc… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Nirmatrelvir or Cariprazine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (2)

  1. Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. Allergan USA Inc (per FDA), Madison, NJ, 2022. DailyMed
  2. Product Information: PAXLOVID(TM) oral tablets, nirmatrelvir oral tablets, ritonavir oral tablets. Pfizer Labs (per FDA), New York, NY, 2024. DailyMed
Was this write-up helpful?

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.